• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Cfic-2015 Nv Family Investments, Llc claimed ownership of 2,083,333 shares (SEC Form 3)

    8/27/24 6:45:22 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NKGN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    CFIC-2015 NV Family Investments, LLC

    (Last) (First) (Middle)
    1120 N. TOWN CENTER DRIVE, SUITE 150

    (Street)
    LAS VEGAS NV 89144

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/12/2024
    3. Issuer Name and Ticker or Trading Symbol
    NKGen Biotech, Inc. [ NKGN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 2,083,333 I See footnote(3)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Convertible promissory note (1) 02/07/2027 Common Stock 1,375,000 $2 I See footnote(3)
    Warrant (1) 08/07/2029 Common Stock 2,750,000 $2 I See footnote(3)
    Option to buy (2) 08/07/2026 Common Stock 2,083,333 (2) I See footnote(3)
    1. Name and Address of Reporting Person*
    CFIC-2015 NV Family Investments, LLC

    (Last) (First) (Middle)
    1120 N. TOWN CENTER DRIVE, SUITE 150

    (Street)
    LAS VEGAS NV 89144

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Cherng Andrew Jin-Chan

    (Last) (First) (Middle)
    1120 N. TOWN CENTER DRIVE, SUITE 150

    (Street)
    LAS VEGAS NV 89144

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    CHERNG PEGGY

    (Last) (First) (Middle)
    1120 N. TOWN CENTER DRIVE, SUITE 150

    (Street)
    LAS VEGAS NV 89144

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. On August 12, 2024, pursuant to a Securities Purchase Agreement dated August 7, 2024, CFIC-2015 NV Family Investments, LLC ("CFIC-2015") acquired from the Issuer a convertible promissory note in the aggregate principal amount of $2,750,000, a warrant to purchase 2,750,000 shares of Common Stock, and 2,083,333 shares of Common Stock as commitment shares. The conversion of the promissory note and the exercise of the warrant are subject to a beneficial ownership limitation and shareholder approval, as described in the respective promissory note and warrant.
    2. On August 7, 2024, CFIC-2015 entered into a Letter Agreement with the Issuer, whereby the Issuer agreed to issue up to 2,083,333 shares of Common Stock to CFIC-2015, upon the purchase by CFIC-2015 of the purchase by CFIC-2015 of up to $2,750,000 aggregate principal amount of convertible promissory notes upon the same terms and conditions as the Securities Purchase Agreement referenced in footnote (1).
    3. Andrew Cherng and Peggy Cherng together own 100% of the voting interests of CFIC-2015.
    /s/ Mecky Wong, Manager of CFIC-2015 NV Family Investments, LLC 08/22/2024
    /s/ Andrew Cherng 08/22/2024
    /s/ Peggy Cherng 08/22/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NKGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NKGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NKGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NKGen Biotech to Present at the Alzheimer's Association International Conference 2025

      SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer's disease during a poster presentation at the upcoming Alzheimer's Association International Conference 2025 ("AAIC 2025") to be held in Toronto, Canada and online from July 27-31, 2025. Presentation details are as follows: Poster Title:Mechanism of Action of Troculeu

      7/22/25 8:05:00 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

      Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in Alzheimer's Disease.Company receives expanded access protocol authorization from the U.S. Food and Drug Administration (FDA) for troculeucel granted to treat patients with known diagnoses of multiple neurodegenerative diseases. IND approval allows for up to 20 patients to be enrolled; first patient enrollment is anticipated in Q3 2025. SANTA ANA, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company foc

      7/21/25 8:00:00 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan

      In connection with HekaBio's recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan. Under Japan's Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class forerunner for the treatment of several intractable neurodegenerative diseases. SANTA ANA, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and

      7/17/25 4:05:00 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      6/2/25 12:11:05 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      5/7/25 4:05:15 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Graf Acquisition Partners Iv Llc disposed of 63,634 shares (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      12/26/24 7:20:39 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Financials

    Live finance-specific insights

    See more
    • NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

      – SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease, expect to initiate Phase I/IIa by year end – SNK02 Phase I allogeneic clinical program continues to progress; anticipated preliminary solid tumor data readout and IND filing for Parkinson's Disease in 1Q24 SANTA ANA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NASDAQ:NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, today announced its financial results for the

      11/14/23 4:48:03 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by NKGen Biotech Inc.

      SC 13G - NKGen Biotech, Inc. (0001845459) (Subject)

      8/22/24 5:22:55 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by NKGen Biotech Inc. (Amendment)

      SC 13G/A - NKGen Biotech, Inc. (0001845459) (Subject)

      5/10/24 2:42:14 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    SEC Filings

    See more
    • NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NKGen Biotech, Inc. (0001845459) (Filer)

      7/17/25 4:33:25 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25-NSE filed by NKGen Biotech Inc.

      25-NSE - NKGen Biotech, Inc. (0001845459) (Subject)

      7/17/25 1:25:20 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - NKGen Biotech, Inc. (0001845459) (Filer)

      7/16/25 5:25:42 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      6/2/25 12:11:05 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      5/7/25 4:05:15 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Leadership Updates

    Live Leadership Updates

    See more
    • NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

      SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator ("PI") for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963). In addition to Dr. Fletcher's appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orl

      2/19/25 8:00:00 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

      SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Gottardis is the owner of, and has served as a consultant at, Gottardis Biotech LLC, a biopharmaceuticals and research and development consultancy firm, since February 2023. Dr. Gottardi

      7/15/24 8:05:00 AM ET
      $JNJ
      $NKGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)